Latest News in the pharma Industry
Top Stories
GSK announces significant new investment in UK manufacturing network
27 Jul 2016
Investment in advanced manufacturing of new respiratory and biopharmaceuticals portfolio.
Read more
BMS Opdivo receives Breakthrough Therapy Designation from FDA for advanced form of bladder cancer
27 Jun 2016
This milestone marks the sixth Breakthrough Therapy Designation for Opdivo.
Read more
Shire completes combination with Baxalta
3 Jun 2016
Combined company expected to deliver double-digit compound annual top-line growth with over $20 billion in annual revenues by 2020.
Read more
Valeant names Joseph C. Papa to be Chairman and CEO of Valeant Pharmaceuticals
25 Apr 2016
Brings more than three decades of leadership and operations experience in healthcare.
Read more
Pfizer–Allergan merger agreement terminated
6 Apr 2016
Allergan reiterates strong standalone growth profile and strategy following termination of Pfizer transaction.
Read more
Engineers develop a pill for long-term drug release
6 Apr 2016
New tablet attaches to the lining of the GI tract, resists being pulled away.
Read more
Sir Andrew Witty to retire from GSK in March 2017
17 Mar 2016
The Board will now conduct a formal search for a successor and will consider internal and external candidates for the role.
Read more
CMA fines pharma companies £45 million
12 Feb 2016
The CMA has fined a number of pharmaceutical companies for anti-competitive conduct and agreements in relation to the supply of paroxetine.
Read more
Shire to combine with Baxalta, creating the global leader in rare diseases
11 Jan 2016
Combination creates leading global biotechnology company projected to deliver double-digit top-line growth with over $20 billion in annual revenues by 2020.
Read more
UBM celebrates securing more than 36000 attendees at biggest ever CPhI Worldwide
7 Jan 2016
World’s largest pharma event sees record exhibitor numbers in Madrid.
Read more
Pfizer and Allergan to combine
23 Nov 2015
As a result of the combination with Allergan and subsequent integration of the two companies, Pfizer now expects to make a decision about a potential separation of the combined company's innovative and established businesses by no later than the end of...
Read more
BMS to sell its HIV R&D portfolio to ViiV Healthcare
18 Dec 2015
Transactions are consistent with the evolution of BMS’s strategic focus, including the decision to discontinue its discovery efforts in virology announced in June.
Read more